John Lunec

Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation.

J. Lunec, M. Tilby, W. Andrews, 2013, Cancer letters.

A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma

Ruth Ladenstein, Gudrun Schleiermacher, Mario Drobics, 2011, Clinical Cancer Research.

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions† †Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluatio

Yan Zhao, Bernard T. Golding, Roger J. Griffin, 2013, MedChemComm.

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Nunzio Iraci, J. Lunec, G. Perini, 2010, Cancer research.

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

N. Curtin, J. Lunec, R. Edmondson, 2017, Oncotarget.

Abstract 4529: Cellular pharmacokinetic and activity studies with the MDM2-p53 inhibitor Nutlin-3

Yan Zhao, David R. Newell, John Lunec, 2010 .

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Per Källblad, N. Curtin, H. Willems, 2005, Bioorganic & medicinal chemistry letters.

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.

Per Källblad, H. Willems, J. Lunec, 2006, Journal of medicinal chemistry.